2.07 USD
0 (0%)
We assign a fundamental rating of 2 out of 10 to AMS. AMS was compared to 100 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of AMS have multiple concerns. AMS has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year AMS has reported negative net income.
AMS had a positive operating cash flow in the past year.
Of the past 5 years AMS 4 years were profitable.
AMS had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -3.84%, AMS is doing worse than 65.35% of the companies in the same industry.
With a Return On Equity value of -9.97%, AMS perfoms like the industry average, outperforming 42.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.84% | ||
| ROE | -9.97% | ||
| ROIC | N/A |
ROA(3y)2.64%
ROA(5y)-1.57%
ROE(3y)5.84%
ROE(5y)-3.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AMS's Profit Margin has improved in the last couple of years.
AMS's Operating Margin has declined in the last couple of years.
With a Gross Margin value of 24.43%, AMS perfoms like the industry average, outperforming 48.51% of the companies in the same industry.
In the last couple of years the Gross Margin of AMS has remained more or less at the same level.
AMS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 24.43% |
OM growth 3Y-20.48%
OM growth 5Y-14.68%
PM growth 3Y92.72%
PM growth 5Y19.22%
GM growth 3Y-5.31%
GM growth 5Y-0.7%
2. Health
2.1 Basic Checks
AMS does not have a ROIC to compare to the WACC, probably because it is not profitable.
AMS has more shares outstanding than it did 1 year ago.
AMS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for AMS is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.84, we must say that AMS is in the distress zone and has some risk of bankruptcy.
AMS has a worse Altman-Z score (0.84) than 75.25% of its industry peers.
A Debt/Equity ratio of 0.58 indicates that AMS is somewhat dependend on debt financing.
AMS's Debt to Equity ratio of 0.58 is in line compared to the rest of the industry. AMS outperforms 58.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.58 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.84 |
ROIC/WACCN/A
WACC9.38%
2.3 Liquidity
A Current Ratio of 1.17 indicates that AMS should not have too much problems paying its short term obligations.
With a Current ratio value of 1.17, AMS perfoms like the industry average, outperforming 42.57% of the companies in the same industry.
A Quick Ratio of 1.17 indicates that AMS should not have too much problems paying its short term obligations.
AMS's Quick ratio of 1.17 is in line compared to the rest of the industry. AMS outperforms 47.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.17 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
The earnings per share for AMS have decreased strongly by -950.00% in the last year.
AMS shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 24.28% yearly.
Looking at the last year, AMS shows a very strong growth in Revenue. The Revenue has grown by 32.90%.
AMS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.58% yearly.
EPS 1Y (TTM)-950%
EPS 3Y121.52%
EPS 5Y24.28%
EPS Q2Q%100%
Revenue 1Y (TTM)32.9%
Revenue growth 3Y17.14%
Revenue growth 5Y6.58%
Sales Q2Q%2.46%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y44.91%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year8.01%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
AMS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AMS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
AMS's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AMS is cheaper than 97.03% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 3.46 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for AMS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSEARCA:AMS (12/5/2025, 8:04:00 PM)
2.07
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners12.71%
Inst Owner Change-2.58%
Ins Owners35.35%
Ins Owner Change4.52%
Market Cap13.54M
Revenue(TTM)28.34M
Net Income(TTM)-2.44M
Analysts80
Price Target4.59 (121.74%)
Short Float %0.18%
Short Ratio0.11
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.21%
Min EPS beat(2)0.99%
Max EPS beat(2)43.42%
EPS beat(4)2
Avg EPS beat(4)-543.23%
Min EPS beat(4)-2080.2%
Max EPS beat(4)43.42%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.46%
Min Revenue beat(2)-3.97%
Max Revenue beat(2)-0.96%
Revenue beat(4)1
Avg Revenue beat(4)0.93%
Min Revenue beat(4)-7.97%
Max Revenue beat(4)16.61%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-9.09%
EPS NY rev (3m)-9.09%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-1.19%
Revenue NY rev (3m)-1.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.46 | ||
| P/FCF | N/A | ||
| P/OCF | 4.71 | ||
| P/B | 0.55 | ||
| P/tB | 0.59 | ||
| EV/EBITDA | 3.46 |
EPS(TTM)-0.34
EYN/A
EPS(NY)-0.12
Fwd EYN/A
FCF(TTM)-1.31
FCFYN/A
OCF(TTM)0.44
OCFY21.25%
SpS4.47
BVpS3.74
TBVpS3.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.84% | ||
| ROE | -9.97% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 24.43% | ||
| FCFM | N/A |
ROA(3y)2.64%
ROA(5y)-1.57%
ROE(3y)5.84%
ROE(5y)-3.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)6.05%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-20.48%
OM growth 5Y-14.68%
PM growth 3Y92.72%
PM growth 5Y19.22%
GM growth 3Y-5.31%
GM growth 5Y-0.7%
F-Score4
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.58 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 2.28 | ||
| Cap/Depr | 182.58% | ||
| Cap/Sales | 39.16% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 46.15% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.17 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 0.84 |
F-Score4
WACC9.38%
ROIC/WACCN/A
Cap/Depr(3y)86.06%
Cap/Depr(5y)59.68%
Cap/Sales(3y)19.8%
Cap/Sales(5y)14.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-950%
EPS 3Y121.52%
EPS 5Y24.28%
EPS Q2Q%100%
EPS Next Y44.91%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)32.9%
Revenue growth 3Y17.14%
Revenue growth 5Y6.58%
Sales Q2Q%2.46%
Revenue Next Year8.01%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-101.77%
EBIT growth 3Y-6.85%
EBIT growth 5Y-9.07%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-255.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-65.59%
OCF growth 3Y-70.14%
OCF growth 5Y-53.93%
AMERICAN SHARED HOSPITAL SER / AMS FAQ
What is the fundamental rating for AMS stock?
ChartMill assigns a fundamental rating of 2 / 10 to AMS.
Can you provide the valuation status for AMERICAN SHARED HOSPITAL SER?
ChartMill assigns a valuation rating of 1 / 10 to AMERICAN SHARED HOSPITAL SER (AMS). This can be considered as Overvalued.
How profitable is AMERICAN SHARED HOSPITAL SER (AMS) stock?
AMERICAN SHARED HOSPITAL SER (AMS) has a profitability rating of 3 / 10.
Can you provide the financial health for AMS stock?
The financial health rating of AMERICAN SHARED HOSPITAL SER (AMS) is 2 / 10.